CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients With High Risk Resected Melanoma

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT02506153
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:27:56.915474+00:00
Published At: 2024-08-27T00:00:00+00:00
Record Updated At: 2026-04-13
Results Posted At: 2024-08-27
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Clinical Stage III Cutaneous Melanoma AJCC v8", "Clinical Stage IV Cutaneous Melanoma AJCC v8", "Metastatic Cutaneous Melanoma", "Metastatic Mucosal Melanoma", "Metastatic Non-Cutaneous Melanoma", "Non-Cutaneous Melanoma", "Recurrent Cutaneous Melanoma", "Recurrent Mucosal Melanoma", "Recurrent Non-Cutaneous Melanoma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2026-04-13"
protocolSection.identificationModule.nctId: "NCT02506153"
protocolSection.identificationModule.officialTitle: "A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients With High Risk Resected Melanoma"
protocolSection.statusModule.overallStatus: "ACTIVE_NOT_RECRUITING"
protocolSection.designModule.phases: ["PHASE3"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: "2024-08-27"

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.